Mark Plavsic
Chief Tech/Sci/R&D Officer presso AURA BIOSCIENCES, INC.
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Il dott. Mark Plavsic è un direttore tecnico presso Fate Therapeutics, Inc. Il Dr. Plavsic è stato precedentemente impiegato come Chief Technical Officer presso Lysogene SA e Head- Process Development & Manufacturing presso Torque Therapeutics, Inc. Si è laureato all'Università di Belgrado e ha conseguito il dottorato all'Università di Belgrado.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
AURA BIOSCIENCES INC
0.26% | 15/03/2024 | 128 515 ( 0.26% ) | 1 M $ | 31/03/2024 |
FATE THERAPEUTICS, INC.
0.12% | 10/01/2023 | 123 705 ( 0.12% ) | 907 995 $ | 31/03/2024 |
Posizioni attive di Mark Plavsic
| Società | Posizione | Inizio |
|---|---|---|
| AURA BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 02/10/2023 |
TeraPore Technologies, Inc.
 TeraPore Technologies, Inc. Chemicals: SpecialtyProcess Industries TeraPore Technologies, Inc. develops cutting-edge membrane technologies for high-permeability, high-resolution nanofiltration. The company was founded by Rachel Dorin in 2013 and is headquartered in | Director/Board Member | - |
Precedenti posizioni note di Mark Plavsic
| Società | Posizione | Fine |
|---|---|---|
| FATE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 06/03/2023 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Torque Therapeutics, Inc.
 Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| LYSOGENE | Chief Tech/Sci/R&D Officer | - |
Formazione di Mark Plavsic
| University of Belgrade | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| AURA BIOSCIENCES, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| LYSOGENE | Commercial Services |
| Aziende private | 3 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Health Technology |
TeraPore Technologies, Inc.
TeraPore Technologies, Inc. Chemicals: SpecialtyProcess Industries TeraPore Technologies, Inc. develops cutting-edge membrane technologies for high-permeability, high-resolution nanofiltration. The company was founded by Rachel Dorin in 2013 and is headquartered in | Process Industries |
- Borsa valori
- Insiders
- Mark Plavsic
